DOCSLIB.ORG

Dendritic Cells Dendritic Cell Recovery After Autologous Stem Cell Transplantation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dendritic Cells Dendritic Cell Recovery After Autologous Stem Cell Transplantation Bone Marrow Transplantation (2002) 30, 261–266 2002 Nature Publishing Group All rights reserved 0268–3369/02 $25.00 www.nature.com/bmt Dendritic cells Dendritic cell recovery after autologous stem cell transplantation D Damiani1, R Stocchi1, P Masolini1, A Michelutti1, A Sperotto1, A Geromin1, C Skert1, M Cerno1, M Michieli3, M Baccarani2 and R Fanin1 1Chair and Division of Haematology, Bone Marrow Transplant Unit, Department of Medical and Morphological Research, University Hospital, Udine, Italy; 2Institute of Haematology and Medical Oncology ‘L and A Sera`gnoli’, University Hospital, Bologna, Italy; and 3Centro di Riferimento Oncologico (CRO), Aviano, Italy Summary: haematologic malignancies and solid tumours. It is now well-recognised that there is persistent immunosuppression There is persistent immunosuppression not only in allo- not only in allogeneic but also in autologous stem cell trans- geneic but also in autologous stem cell transplantation plantation because humoral and cellular immunity may take because humoral and cellular immunity may take a year a year or more to return to normal, with increased risk of or more to return to normal, with increased risk of infectious complications.1 Functional reconstitution of the infectious complications. This immune defect may also lymphoid compartment after autologous bone marrow/ involve antigen presentation, in particular dendritic cell peripheral blood HSCT depends either on the presence of (DC) function. We evaluated DC subset reconstitution adequate numbers of antigen-specific T and B cells in the in 58 patients who underwent bone marrow (BM) or transplant or the maturation of lymphoid progenitors and peripheral blood (PB) autologous haematopoietic stem perhaps multipotent stem cells into antigen-specific T and cell transplantation (HSCT). In all patients DC type 1 B cells within thymic and bone marrow microenviron- (DC1) and DC type 2 (DC2) were already significantly ments. The early post-transplant period is characterised by lower than in normal individuals before conditioning a reduction of CD4+ T cells (due to a persistently low level therapy (DC1/␮l 3.1 ؎ 1.0, DC2/␮l 3.0 ؎ 1.1). On day of naive CD4+/CD45RA+ T cells) and by elevated numbers and day ؉7 the mean DC1 and DC2 numbers were of CD8+ T cells. The number of B cells is also reduced.2–7 0 very low in both groups. Patients who received unman- This immune defect may also involve antigen presentation. ipulated marrow or peripheral blood stem cells reached On this subject, it has been suggested that the patients’ anti- pre-conditioning levels of DC1 and DC2 cells on day gen presenting cells (APC) are abnormal either numerically ؉20. In patients receiving selected CD34 cells, DC or functionally after transplant.8 Dendritic cells (DC) are increased slowly and pre-transplant counts were the most powerful APC in inducing T cell activation. They ;observed only on day ؉60. Nearly ‘normal’ levels of originate from pluripotent stem cells in the bone marrow DC1 and DC2 could be observed in the first group from then, they migrate from peripheral blood to tissues, where .day ؉180, and were maintained thereafter; in CD34ϩ they achieve the capacity to capture and process antigens selected patients DC1 and DC2 counts remained lower In lymphoid organs DC present these processed antigens to than normal. Our data emphasise that circulating anti- and activate T cells.9 gen presenting cells (APC) recover quickly. It remains Recently, two subsets of DC have been identified in per- to be determined if DC frequency in PB reflects their ipheral blood. DC type 1 (lineage negative, HLA-DR posi- tissue function. The relatively low incidence of infections tive and CD11c positive) are myeloid and activate (through in patients undergoing autologous transplantation, interaction between CD80 and CD28, in the presence of despite defective lymphocyte reconstitution, could be IL-12) T helper type 1 (Th1), which produce IL-1 and IFN␥ related to functionally efficient DC. (pro-inflammatory cytokines); DC type 2 (lineage negative, Bone Marrow Transplantation (2002) 30, 261–266. HLA-DR positive and CD123 positive) may be lymphoid doi:10.1038/sj.bmt.1703637 and activate (through interaction between CD86 and CD28, Keywords: dendritic cell; autologous stem cell transplan- in the presence of IL-10) T helper type 2 (Th2), which tation; immunological recovery produce IL-4 and IL-10 (anti-inflammatory cytokines).8,10–12 In this paper we evaluated the kinetics of lymphocyte and dendritic cell subset reconstitution in 58 patients undergo- ing bone marrow or peripheral blood autologous HSCT and High-dose chemotherapy followed by haemopoietic stem its relationship with infectious complications. cell transplantation (HSCT) is increasingly used for various Patients and methods Correspondence: Dr D Damiani, Division of Haematology, University Hospital, P le S Maria della Misericordia, 33100 Udine, Italy The kinetics of lymphocyte and dendritic cell reconstitution Received 26 September 2001; accepted 1 May 2002 were studied in 58 consecutive patients affected by NHL Dendritic cell recovery D Damiani et al 262 (n ϭ 28), HL (n ϭ 6), multiple myeloma (n ϭ 15), acute tive controls, with irrelevant isotypic antibodies were pre- leukaemias (n ϭ 4) and breast cancer (n ϭ 5) who received pared in each experiment, as appropriate. The absolute intensification therapy and autologous stem cell rescue number of dendritic cells was calculated from the WBC (HSCT) from January 1997 to December 2000. Patients count multiplied by the proportion of each subpopulation with NHL received the BAVC (cytosine-arabinoside, eto- among the WBC, as determined by flow cytometric analy- poside, cyclophosphamide and carmustine) conditioning sis. Data were expressed as DC1 and DC2 mean number regimen, patients with HL received the BEAM (cytosine- Ϯ 2 standard deviation per microliter of PB. arabinoside, etoposide, melphalan and carmustine) con- ditioning regimen, myeloma patients received busulphan Immune reconstitution and melphalan, patients with acute leukemia received bus- ulphan and cyclophosphamide and breast cancer patients Peripheral blood lymphocyte subsets were analysed by flow received etoposide, carboplatinum and iphosphamide. A cytometry before starting the conditioning regimen, at time median of 2.6 ϫ 106/kg (range 0.77–4) CD34ϩ cells were 0, before stem cell infusion, at time ϩ30, ϩ60, ϩ90, ϩ240, infused in peripheral blood HSCT (n ϭ 46) and 1.07 ϫ ϩ360, ϩ3 years. One hundred ␮l of peripheral blood anti- 106/kg (range 0.4–1.87) in bone marrow HSCT (n ϭ 12). coagulated with EDTA were incubated at laboratory tem- Twelve of 15 myeloma patients received highly purified perature for 20 min with the following monoclonal anti- CD34ϩ stem cells (median 2.8 ϫ 106/kg, range 2–5), bodies: CD3FITC, CD19PE, CD4PE, CD8FITC, CD16PE, obtained after immumomagnetic separation by CliniMacs CD56PE, CD45ROFITC, CD45RAFITC. At the end of (Miltenyi Biotec, Bergisch Gladbach, Germany). Antibiotic incubation red cells were lysed by Facs Lysis solution (BD, prophylaxis included ciprofloxacin and itraconazole. G- Bruxelles, Belgium), washed twice and analysed within 1 h. CSF (filgrastim, Neupogen, Amgen, Thousand Oaks, CA, Acquisition and analysis were performed with a FacsCali- USA) at a dose of 5 ␮g/kg was administered from day bur (BD) flow cytometer with Lysis II software. WBC cell ϩ4, until the leukocyte count exceeded 2 ϫ 109/l for 3 counts were determined using an automated cell counter consecutive days. Patients’ characteristics are summarised (CELL DYN 3200). in Table 1. Total lymphocyte count was determined by flow cytome- try by incubating a sample of whole blood with the Dendritic cell reconstitution CD14PE/CD45FITC (BD) antibodies. The absolute number of lymphocytes was calculated by multiplying the percent- Dendritic cell recovery was evaluated before starting the age of CD14−/CD45ϩϩ by the total WBC. The absolute conditioning regimen, at day 0 before stem cell infusion, number of cells in any given lymphocyte population was at day ϩ7 and at the same points as lymphocytes. DC1 calculated by multiplying the percentage of positive cells (CD11cϩ, myeloid origin) and DC2 (CD123ϩ, lymphoid for each lymphocyte marker by the absolute lymphocyte origin) subsets were identified by using a three-colour flow number. Data were expressed as mean number Ϯ 2 cytometric assay on lysed whole blood to minimise selec- standard deviations per microliter of PB. tive loss. For each test 100 ␮l of blood were incubated with ␮ ␮ 10 l of the HLA-DR-PerCP (BD), with 20 l of a mixture Normal controls of lineage-related antibodies FITC (lineage cocktail 1 FITC, BD), including the following monoclonal antibodies: Circulating dendritic cell and lymphocyte subsets of 15 CD3, CD14, CD16, CD19, CD20 and CD56, and with 10 healthy donors were evaluated as described above, to obtain ␮l of the CD11c-PE or the CD123-PE antibodies. At the normal reference values. end of a 15 min incubation, red cells were lysed as described above, samples were washed twice and immedi- Data analysis ately analysed. A minimum of 50 000 events was acquired for each experiment. Dendritic cells express high levels of Mean differences at different times between patients and HLA-DR and lack lineage-related antigens. After gating normal controls were assessed by the Mann–Whitney U lineage-negative events, the two DC1 and DC2 subsets test. were identified in the high HLA-DR expressing population, on the basis of their high CD11c or CD123 intensity. Nega- Results Table 1 Patient characteristics Transplant-related data are summarised in Tables 2 and 3. Not selected Selected Haematological recovery occurred promptly in all patients, without any differences between patients receiving bone Patients 46 12 marrow or peripheral blood stem cells. The median time to Sex (M/F) 28/18 7/5 reach a neutrophil count >1 ϫ 109/l was day ϩ10 (9–14) Median age 40 (16–58) 55 (41–63) in PB patients, day ϩ13 (11–15) in PB selected patients Disease 28/46 NHL 12/12 MM and day ϩ12 (10–30) in BM patients.
Load more

Recommended publications
  • Pearls of Laboratory Medicine Transcript Document
    Pearls of Laboratory Medicine www.traineecouncil.org TITLE: Transfusion Support in Hematopoietic Stem Cell Transplant PRESENTER: Erin K. Meyer, DO, MPH Slide 1: Title Slide Hello, my name is Erin Meyer. I am the medical director of apheresis and associate medical director of Transfusion Services at Nationwide Children’s Hospital in Columbus Ohio. Welcome to this Pearl of Laboratory Medicine on “Transfusion Support in Hematopoietic Stem Cell Transplant or HSCT.” Slide 2: Transfusion Support for Hematopoietic Stem Cell Transplant (HSCT) The objectives of my talk are a brief overview of the different types of HSCT followed by a review of the sources of HSCT available and transfusion thresholds for patients receiving the different types of HSCT. Finally, I will discuss ABO-incompatible HSCT with a focus on the complications of and transfusion support for each possible ABO-incompatible combination. Hematopoietic stem cells came to light after the dropping of the atomic bombs in 1945. People who survived the initial explosions later died of bone marrow failure from radiation. A series of sentinel experiments by Till and McCulloch in the 1960s then showed that transfer of bone marrow cells from donor mice into lethally irradiated recipient mice resulted in the formation of colonies of myeloid, erythroid, and megakaryocytic cells in the recipient’s spleen approximately 7-14 days later. Stem cells have two very unique properties: the ability to self-renew and the ability to regenerate. The field of stem cell biology has only grown and HSCTs are able to be transplanted now to recipients to help a variety of diseases.
    [Show full text]
  • Hematopoietic Stem Cell Therapy) in MS
    FAQ About HSCT (Hematopoietic Stem Cell Therapy) in MS There is growing evidence that autologous HSCT is not for everyone with MS but may be highly effective for people with relapsing MS who meet very specific characteristics. The National Medical Advisory Committee of the National MS Society has written an article reviewing evidence related to the optimal use of autologous hematopoietic stem cell transplantation (aHSCT, commonly known as bone marrow transplants) for the treatment of specific types of relapsing multiple sclerosis. The committee’s findings are published in JAMA Neurology (online October 26, 2020). Q. What is HSCT for multiple sclerosis? A. HSCT (Hematopoietic Stem Cell Transplantation) attempts to “reboot” the immune system, which is responsible for damaging the brain and spinal cord in MS. In HSCT for MS, hematopoietic (blood cell-producing) stem cells, which are derived from a person’s own (“autologous”) bone marrow or blood, are collected and stored, and the rest of the individual’s immune cells are depleted by chemotherapy. Then the stored hematopoietic stem cells are reintroduced to the body. The new stem cells migrate to the bone marrow and over time produce new white blood cells. Eventually they repopulate the body with immune cells. Q. What is the idea behind autologous HSCT (aHSCT) for MS? A. The goal of aHSCT is to reset the immune system and stop the inflammation that contributes to active relapsing MS. Q. Is aHSCT an FDA-approved therapy option for people with MS? A. The medications and procedures used in aHSCT are already approved by the FDA. Publication of the outcomes from well-controlled clinical studies of aHSCT therapy will encourage greater acceptance and use by the medical community.
    [Show full text]
  • The Distribution of Immune Cells in the Uveal Tract of the Normal Eye
    THE DISTRIBUTION OF IMMUNE CELLS IN THE UVEAL TRACT OF THE NORMAL EYE PAUL G. McMENAMIN Perth, Western Australia SUMMARY function of these cells in the normal iris, ciliary body Inflammatory and immune-mediated diseases of the and choroid. The role of such cell types in ocular eye are not purely the consequence of infiltrating inflammation, which will be discussed by other inflammatory cells but may be initiated or propagated authors in this issue, is not the major focus of this by immune cells which are resident or trafficking review; however, a few issues will be briefly through the normal eye. The uveal tract in particular considered where appropriate. is the major site of many such cells, including resident tissue macro phages, dendritic cells and mast cells. This MACRO PHAGES review considers the distribution and location of these and other cells in the iris, ciliary body and choroid in Mononuclear phagocytes arise from bone marrow the normal eye. The uveal tract contains rich networks precursors and after a brief journey in the blood as of both resident macrophages and MHe class 11+ monocytes immigrate into tissues to become macro­ dendritic cells. The latter appear strategically located to phages. In their mature form they are widely act as sentinels for capturing and sampling blood-borne distributed throughout the body. Macrophages are and intraocular antigens. Large numbers of mast cells professional phagocytes and play a pivotal role as are present in the choroid of most species but are effector cells in cell-mediated immunity and inflam­ virtually absent from the anterior uvea in many mation.1 In addition, due to their active secretion of a laboratory animals; however, the human iris does range of important biologically active molecules such contain mast cells.
    [Show full text]
  • Development of Plasmacytoid and Conventional Dendritic Cell Subtypes from Single Precursor Cells Derived in Vitro and in Vivo
    ARTICLES Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo Shalin H Naik1,2, Priyanka Sathe1,3, Hae-Young Park1,4, Donald Metcalf1, Anna I Proietto1,3, Aleksander Dakic1, Sebastian Carotta1, Meredith O’Keeffe1,4, Melanie Bahlo1, Anthony Papenfuss1, Jong-Young Kwak1,4,LiWu1 & Ken Shortman1 The development of functionally specialized subtypes of dendritic cells (DCs) can be modeled through the culture of bone marrow with the ligand for the cytokine receptor Flt3. Such cultures produce DCs resembling spleen plasmacytoid DCs (pDCs), http://www.nature.com/natureimmunology CD8+ conventional DCs (cDCs) and CD8– cDCs. Here we isolated two sequential DC-committed precursor cells from such cultures: dividing ‘pro-DCs’, which gave rise to transitional ‘pre-DCs’ en route to differentiating into the three distinct DC subtypes (pDCs, CD8+ cDCs and CD8– cDCs). We also isolated an in vivo equivalent of the DC-committed pro-DC precursor cell, which also gave rise to the three DC subtypes. Clonal analysis of the progeny of individual pro-DC precursors demonstrated that some pro-DC precursors gave rise to all three DC subtypes, some produced cDCs but not pDCs, and some were fully committed to a single DC subtype. Thus, commitment to particular DC subtypes begins mainly at this pro-DC stage. Dendritic cells (DCs) are antigen-presenting cells crucial for the innate macrophages12. Further ‘downstream’, ‘immediate’ precursors have and adaptive response to infection as well as for maintaining immune been identified for several DC types, including Ly6Chi monocytes as 3,4,6 13 Nature Publishing Group Group Nature Publishing tolerance to self tissue.
    [Show full text]
  • IDF Guide to Hematopoietic Stem Cell Transplantation
    Guide to Hematopoietic Stem Cell Transplantation Immune Deficiency Foundation Guide to Hematopoietic Stem Cell Transplantation This publication contains general medical information that cannot be applied safely to any individual case. Medical knowledge and practice can change rapidly. Therefore, this publication should not be used as a substitute for professional medical advice. In all cases, patients and caregivers should consult their healthcare providers. Each patient’s condition and treatment are unique. Copyright 2018 by Immune Deficiency Foundation, USA Readers may redistribute this guide to other individuals for non-commercial use, provided that the text, html codes, and this notice remain intact and unaltered in any way. Immune Deficiency Foundation Guide to Hematopoietic Stem Cell Transplantation may not be resold, reprinted or redistributed for compensation of any kind without prior written permission from the Immune Deficiency Foundation (IDF). If you have any questions about permission, please contact: Immune Deficiency Foundation, 110 West Road, Suite 300, Towson, MD 21204, USA, or by telephone: 800-296-4433. For more information about IDF, go to: www.primaryimmune.org. This publication has been made possible through the IDF SCID Initiative and the SCID, Angels for Life Foundation. Acknowledgements The Immune Deficiency Foundation would like to thank the organizations and individuals who helped make this publication possible and contributed to the development of the Immune Deficiency Foundation Guide to Hematopoietic Stem
    [Show full text]
  • Stem Cell Hematopoiesis
    Hematopoietic and Lymphoid Neoplasm Project Introduction to the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues 4th edition 2 Hematopoietic and Lymphoid Lineages, Part I Steven Peace, CTR Westat September 2009 3 Objectives • Understand stem cell hematopoiesis • Understand proliferation • Understand differentiation • Provide a History of Classification of Tumors of Hematopoietic and Lymphoid Tissues • Understand the delineation of cell lines (lineage) in relation to the WHO Classification 4 Objectives (2) • Introduce WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 4th ed. • Introduce NEW ICD-O histology codes • Introduce NEW reportable conditions 5 Stem Cell Hematopoiesis • What is a hematopoietic stem cell? • Where are hematopoietic stem cells found? • What is Hematopoiesis? • Hematopoietic stem cells give rise to ALL blood cell types including; • Myeloid lineages • Lymphoid lineages 6 Hematopoietic stem cells give rise to two major progenitor cell lineages, myeloid and lymphoid progenitors Regenerative Medicine, 2006. http://www.dentalarticles.com/images/hematopoiesis.png 7 Proliferation and Differentiation • Regulation of proliferation • Regulation of differentiation • Both affect development along cell line • Turn on/Turn off • Growth factors • Genes (including mutations) • Proteins • Ongogenesis – becoming malignant 8 Blood Lines – Donald Metcalf, AlphaMED Press, 2005 Figure 3.2 The eight major hematopoietic lineages generated by self-renewing multipotential stem cellsB Copyright © 2008 by AlphaMed
    [Show full text]
  • The Importance of Dendritic Cells in Maintaining Immune Tolerance Cindy Audiger, M
    The Importance of Dendritic Cells in Maintaining Immune Tolerance Cindy Audiger, M. Jubayer Rahman, Tae Jin Yun, Kristin V. Tarbell and Sylvie Lesage This information is current as of October 1, 2021. J Immunol 2017; 198:2223-2231; ; doi: 10.4049/jimmunol.1601629 http://www.jimmunol.org/content/198/6/2223 Downloaded from References This article cites 166 articles, 73 of which you can access for free at: http://www.jimmunol.org/content/198/6/2223.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on October 1, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2017 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Th eJournal of Brief Reviews Immunology The Importance of Dendritic Cells in Maintaining Immune Tolerance x { Cindy Audiger,*,†,1 M. Jubayer Rahman,‡,1 Tae Jin Yun, , Kristin V. Tarbell,‡ and Sylvie Lesage*,† Immune tolerance is necessary to prevent the immune specific depletion of CD11c+ cells (3).
    [Show full text]
  • Cell Division History Determines Hematopoietic Stem Cell Potency Fumio Arai1,†,*, Patrick S
    bioRxiv preprint doi: https://doi.org/10.1101/503813; this version posted January 15, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Cell Division History Determines Hematopoietic Stem Cell Potency Fumio Arai1,†,*, Patrick S. Stumpf2,†, Yoshiko M. Ikushima3,†, Kentaro Hosokawa1, Aline Roch4, Matthias P. Lutolf4, Toshio Suda5, and Ben D. MacArthur2,6,7,* †† 1Department of Stem Cell Biology and Medicine, Graduate School of Medical Sciences, Kyushu University, 812-8582, Fukuoka, Japan. 2Centre for Human Development, Stem Cells and Regeneration, University of Southampton, SO17 1BJ, UK 3Research Institute National Center for Global Health and Medicine, Tokyo, Japan 4Laboratory of Stem Cell Bioengineering, Institute of Bioengineering, School of Life Sciences and School of Engineering, Ecole Polytechnique Federale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland 5Cancer Science Institute, National University of Singapore, 14 Medical Drive, MD6, 117599 Singapore, Singapore 6Institute for Life Sciences, University of Southampton, SO17 1BJ, United Kingdom 7Mathematical Sciences, University of Southampton, SO17 1BJ, United Kingdom *Correspondence to Fumio Arai ([email protected]) and Ben MacArthur ([email protected]) †These authors contributed equally. ††Lead Author ABSTRACT Loss of stem cell self-renewal may underpin aging. Here, we combined single cell profiling, deep-learning, mathematical modelling and in vivo functional studies to explore how hematopoietic stem cell (HSC) division patterns evolve with age. We trained an artificial neural network (ANN) to accurately identify cell types in the hematopoietic hierarchy and predict their age from their gene expression patterns.
    [Show full text]
  • Immunology 101
    Immunology 101 Justin Kline, M.D. Assistant Professor of Medicine Section of Hematology/Oncology Committee on Immunology University of Chicago Medicine Disclosures • I served as a consultant on Advisory Boards for Merck and Seattle Genetics. • I will discuss non-FDA-approved therapies for cancer 2 Outline • Innate and adaptive immune systems – brief intro • How immune responses against cancer are generated • Cancer antigens in the era of cancer exome sequencing • Dendritic cells • T cells • Cancer immune evasion • Cancer immunotherapies – brief intro 3 The immune system • Evolved to provide protection against invasive pathogens • Consists of a variety of cells and proteins whose purpose is to generate immune responses against micro-organisms • The immune system is “educated” to attack foreign invaders, but at the same time, leave healthy, self-tissues unharmed • The immune system can sometimes recognize and kill cancer cells • 2 main branches • Innate immune system – Initial responders • Adaptive immune system – Tailored attack 4 The immune system – a division of labor Innate immune system • Initial recognition of non-self (i.e. infection, cancer) • Comprised of cells (granulocytes, monocytes, dendritic cells and NK cells) and proteins (complement) • Recognizes non-self via receptors that “see” microbial structures (cell wall components, DNA, RNA) • Pattern recognition receptors (PRRs) • Necessary for priming adaptive immune responses 5 The immune system – a division of labor Adaptive immune system • Provides nearly unlimited diversity of receptors to protect the host from infection • B cells and T cells • Have unique receptors generated during development • B cells produce antibodies which help fight infection • T cells patrol for infected or cancerous cells • Recognize “foreign” or abnormal proteins on the cell surface • 100,000,000 unique T cells are present in all of us • Retains “memory” against infections and in some cases, cancer.
    [Show full text]
  • Granulocytes, Macrophages, and Dendritic Cells Arise from A
    Proc. Natl. Acad. Sci. USA Vol. 90, pp. 3038-3042, April 1993 Immunology Granulocytes, macrophages, and dendritic cells arise from a common major histocompatibility complex class II-negative progenitor in mouse bone marrow KAYO INABA*t, MUNEO INABA*, MASASHI DEGUCHI*, KATSUHIKO HAGI*, RYoJi YASUMIZUf, SUSUMU IKEHARAt, SHIGERU MURAMATSU*, AND RALPH M. STEINMAN§ *Department of Zoology, Faculty of Science, Kyoto University, Sakyo, Kyoto 606, Japan; tFirst Department of Pathology, Kansai Medical University, Moriguchi, Osaka 570, Japan; and §Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, NY 10021 Communicated by Zanvil A. Cohn, December 21, 1992 ABSTRACT The developmental origin of dendritic cells, a lineage-restricted macrophage and granulocyte colony- specialized system ofmajor histocompatibility complex (MHC) stimulating factors (M-CSF and G-CSF, respectively) (8, 10, class 11-rich antigen-presenting cells for T-celi immunity and 12). tolerance, is not well characterized. Granulocyte-macrophage Since GM-CSF can induce the formation of mixed popu- colony-stimulating factor (GM-CSF) is known to stimulate lations ofgranulocytes and macrophages in semi-solid colony dendritic cells, including growth and development from MHC systems (15), we asked whether dendritic cells could also class 11-negative precursors in suspension cultures of mouse arise from a colony-forming precursor that is common to bone marrow. Here we studied colony formation in semi-solid phagocytes. Cells with some of the features of dendritic cells methylcellulose cultures, a classical bioassay system in which have been detected in human cell colonies that were induced GM-CSF induces the formation of mixed granulocyte- with lectin-conditioned medium (16) and more recently with macrophage colonies.
    [Show full text]
  • Differential Contributions of Haematopoietic Stem Cells to Foetal and Adult Haematopoiesis: Insights from Functional Analysis of Transcriptional Regulators
    Oncogene (2007) 26, 6750–6765 & 2007 Nature Publishing Group All rights reserved 0950-9232/07 $30.00 www.nature.com/onc REVIEW Differential contributions of haematopoietic stem cells to foetal and adult haematopoiesis: insights from functional analysis of transcriptional regulators C Pina and T Enver MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK An increasing number of molecules have been identified ment and appropriate differentiation down the various as candidate regulators of stem cell fates through their lineages. involvement in leukaemia or via post-genomic gene dis- In the adult organism, HSC give rise to differentiated covery approaches.A full understanding of the function progeny following a series of relatively well-defined steps of these molecules requires (1) detailed knowledge of during the course of which cells lose proliferative the gene networks in which they participate and (2) an potential and multilineage differentiation capacity and appreciation of how these networks vary as cells progress progressively acquire characteristics of terminally differ- through the haematopoietic cell hierarchy.An additional entiated mature cells (reviewed in Kondo et al., 2003). layer of complexity is added by the occurrence of different As depicted in Figure 1, the more primitive cells in the haematopoietic cell hierarchies at different stages of haematopoietic differentiation hierarchy are long-term ontogeny.Beyond these issues of cell context dependence, repopulating HSC (LT-HSC),
    [Show full text]
  • Transfusion Support Issues in Hematopoietic Stem Cell Transplantation Claudia S
    Knowledge of transfusion complications related to HSCT can help with the early detection and treatment of patients before and after transplantation. Ray Paul. SP12-6796 × 40, 2013. Acrylic, latex, enamel on canvas printed with an image of myxofibrosarcoma with metastases to the artist’s lung, 26" × 36". Transfusion Support Issues in Hematopoietic Stem Cell Transplantation Claudia S. Cohn, MD, PhD Background: Patients receiving hematopoietic stem cell transplantation require extensive transfusion support until red blood cell and platelet engraftment occurs. Rare but predictable complications may arise when the transplanted stem cells are incompatible with the native ABO type of the patient. Immediate and delayed hemolysis is often seen. Methods: A literature review was performed and the results from peer-reviewed papers that contained reproducible findings were integrated. Results: A strong body of clinical evidence has developed around the common complications experienced with ABO-incompatible hematopoietic stem cell transplantation. These complications are discussed and the underlying pathophysiology is explained. General treatment options and guidelines are enumerated. Conclusions: ABO-incompatible hematopoietic stem cell transplantations are frequently performed. Immune-related hemolysis is a commonly encountered complication; therefore, health care professionals must recognize the signs of immune-mediated hemolysis and understand the various etiologies that may drive the process. Introduction antigen (HLA) matching remains an important predic- Hematopoietic stem cell transplantation (HSCT) is used tor of success with HSCT; however, the ABO barrier is to treat a variety of hematological and congenital diseas- often crossed when searching for the most appropriate es. The duration and specificity of transfusion support HLA match between donor and patient.
    [Show full text]